England [UK], August 30 (ANI): A comprehensive clinical trial sponsored by University College London (UCL), the University of East Anglia, and Guy’s and St Thomas’ NHS Foundation Trust found that sinus surgery is more effective than antibiotics at treating chronic rhinosinusitis.
One in every ten people in the United Kingdom suffers from chronic rhinosinusitis (CRS), sometimes known as sinusitis. Symptoms include a blocked and runny nose, loss of smell, facial pain, fatigue, and worsening of respiratory difficulties, such as asthma. It generally resembles the symptoms of a bad cold, but it can persist for months or even years.
The team conducted a randomised controlled patient trial comparing sinus surgery with long-term antibiotic use and a placebo.
More than 500 patients from around the UK participated, all of whom used nasal steroids and saline rinses as part of their usual care – both of which have been shown to help alleviate the condition.
The researchers found that surgery was effective at relieving sinusitis symptoms, and trial participants who underwent surgery were still feeling better six months later, according to the findings published in The Lancet. Of those who underwent surgery, 87 per cent said their quality of life had improved six months on.
A three-month course of low-dose antibiotics was not found to be helpful, as there was no significant difference in outcomes between those on antibiotics and those in the placebo arm of the trial.
The study is part of the MACRO programme, involving a collaborative group of researchers from UCL (the trial’s sponsor), the University of East Anglia (UEA), Guy’s and St Thomas’ NHS Foundation Trust, the University of Southampton, the University of Oxford, UCLH, and Imperial College London. The programme is funded by the National Institute for Health and Care Research.
Lead author Professor Carl Philpott, from UEA’s Norwich Medical School, one of the Chief Investigators of the MACRO trial, said, “Chronic rhinosinusitis causes the spaces inside the nose and head, called sinuses, to become inflamed and swollen. This common condition keeps mucus from draining. It gives patients a very stuffy nose, breathing through the nose can be really hard, and it is the major underlying cause of smell loss in the general population. What we found is that surgery was effective at reducing symptoms six months on, while taking the course of antibiotics seemed to make little difference.”
“We hope our findings will help reduce the length of time for patients to get treatment. Streamlining clinical pathways will help reduce unnecessary visits and consultations, and save on healthcare resources.”
For the trial, all participants received nasal steroids and saline rinses as standard care, alongside their randomly allocated treatment option of either sinus surgery, antibiotics or placebo tablets. They were followed up after three and six months, where researchers examined their nose and sinuses, took airflow readings and conducted smell tests, to gauge the success of each treatment in terms of improvement of symptoms, quality of life and possible side effects.
Professor Claire Hopkins (Guy’s Hospital, London), one of the Chief Investigators of the MACRO trial, said, “Although sinus surgery is commonly performed within the NHS, uncertainty regarding its effectiveness has led to restricted access for many patients in the NHS. The results of the MACRO trial highlight the significant improvements in quality of life that many patients experience after surgery, and should give them and their referring primary care doctors more confidence in seeking treatment for chronic rhinosinusitis. We hope that this work will enhance the care for adult patients with chronic rhinosinusitis within the NHS, and beyond.”
Study co-author Professor Anne Schilder (UCL Ear Institute), director of the NIHR UCLH Biomedical Research Centre Hearing Health Theme, who is leading the project at UCL, commented, “Here we have provided robust evidence that surgery is an effective means to treat chronic rhinosinusitis when local treatments have failed, which should be welcome news to the large numbers of people with the condition.”
“The MACRO trial has shown the value of research collaboration across specialities and organisations. It was the first NIHR programme grant for our speciality, recognising the need for better evidence for the management of common ENT conditions and the strength of our collaborative team. The commitment of our investigators, research nurses and of course our patient participants across 20 UK sites made it a success.”
Jim Boardman, MACRO patient representative, said, “I’ve lived under a cloud for years with CRS, as have many others I’ve met with the same condition. There’s a persistent headache and blocked nose along with the loss of sense of smell, which removes a whole dimension of everyday experience and enjoyment. A clear path to successful treatment will be welcomed by all CRS sufferers.”
The researchers are now continuing their research to assess the cost-effectiveness of sinus surgery, while also continuing to follow up trial participants over longer periods of time to see how long the benefits last. (ANI)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
